{
    "clinical_study": {
        "@rank": "144600", 
        "acronym": "Beva", 
        "arm_group": {
            "arm_group_label": "bevacizumab, inflammatory breast cancer", 
            "arm_group_type": "Experimental", 
            "description": "Neoadjuvant therapy associating bevacizumab, cyclophosphamide, fluorouracil and epirubicin hydrochloride q3w, 4 cycles Adjuvant therapy by docetaxel q3w, 4 cycles +/- trastuzumab q3w, 18 cycles if tumors overexpress HER2"
        }, 
        "brief_summary": {
            "textblock": "Multi-center, non randomised, open label, non controlled pilot study. Evaluating the\n      treatment of bevacizumab in association with pre-operative chemotherapy, followed by\n      surgery, adjuvant chemotherapy and radiotherapy in Patients with inflammatory breast cancer."
        }, 
        "brief_title": "Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Inflammatory Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Inflammatory Breast Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Pilot study evaluating the safety and efficacy of adding Bevacizumab to neoadjuvant\n      chemotherapy in patients presenting non metastatic inflammatory breast cancer (IBC).\n      Patients will receive 4 cycles of chemotherapy FEC100 associating Fluorouracil (500 mg/m2),\n      Epirubicin (100 mg/m2), Cyclophosphamide (500 mg/m2) and Bevacizumab 15 mg/kg every at day 1\n      of ecah 21 days cycle for 4 cycles. Six weeks after the end of neoadjuvant chemotherapy,\n      patients will undergo mastectomy and 4 cycles of Docetaxel (100 mg/m2)as adjuvant\n      chemotherapy +/-Trastuzumab 8 mg/kg for the first cycle then 6mg/kg every 3 weeks for 17\n      cycles if tumor overexpress Human Epidermal Growth Factor Receptor 2 (HER2).\n\n      The primary objective of this study is to evaluate the safety and the efficacy, i.e.\n      pathologic complete response (pCR) after 4 cycles of FEC100+Bevacizumab in IBC"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Patients must have signed a written informed consent form prior to any study\n             specific procedures,\n\n               -  Women,\n\n               -  20 years or older,\n\n               -  Performance status  < 2 (ECOG),\n\n               -  Histologically confirmed inflammatory breast cancer T4d  any N,\n\n               -  hormonal Status known,\n\n               -  no metastases according to the last TNM classification,\n\n               -  adequate hematologic function :\n\n                    -  absolute neutrophil count \u2265 1 500/mm3\n\n                    -  Platelets \u2265 100 000/mm3\n\n                    -  Hemoglobin \u2265 9 g/dL\n\n               -  adequate liver function :\n\n                    -  ASAT and ALAT  < \u00e0 3 ULN\n\n                    -  Alkaline Phosphatase < 5 ULN\n\n                    -  Total bilirubin < 1,5 ULN, o\n\n               -  adequate kidney function :\n\n                    -  creatinine < 1,5 x normal or creatinine Clearance \u2265 50ml/min (according to\n                       the cockcroft and Gault formula)\n\n                    -  Urine Dipstick for proteinuria < 2+ patients who have proteinuria \u2265 2 + on\n                       dipstick urinalysis at baseline should undergo a 24 hours urine  collection\n                       and must demonstrate  \u2264 1 g of protein in 24 hours,\n\n               -  adequate coagulation and cardiac  function :\n\n                    -  Prothrombin ratio \u2265 70 % and,\n\n                    -  Prothrombin time \u2264 1,5 upper limit of normal (ULN) within 7 days prior to\n                       enrolment\n\n                    -  Left Ventricular ejection fraction (LVEF) \u2265 55 %\n\n        Exclusion Criteria:\n\n          -  Patients of childbearing potential with a positive pregnancy test (serum or urine)\n             prior to enrollment\n\n          -  Patients who are either not post-menopausal, or surgically sterile, not using\n             \"effective contraception\" (the definition of \"effective contraception\" will be based\n             on the judgment of the investigator)\n\n          -  Patients who are pregnant or breastfeeding\n\n          -  Patient considered socially or psychological unable to comply with the treatment and\n             the required medial follow-up,\n\n          -  Concurrent participation in another clinical trial or treatment with any other\n             anticancer agent during the protocol specified period\n\n          -  Patients unwilling or unable to sign and date an Ethics Committee (EC)/ Institutional\n             Review Board (IRB)-approved patient informed consent form\n\n          -  Patients unwilling or unable to comply with scheduled visits, treatment plans,\n             laboratory tests, and other study procedures\n\n          -  Non inflammatory breast cancer with lymphatic skin permeation, Metastases,\n\n          -  Bilateral breast cancer\n\n          -  Distant metastases (stage IV)\n\n          -  History of another cancer other than adequately treated carcinoma in situ of the\n             cervix uteri, basal or squamous cell skin cancer\n\n          -  Prior anti tumor therapy (surgery, radiotherapy, chemotherapy, hormonal treatment and\n             targeted therapy) except treatments given for carcinoma in situ of the cervix uteri,\n             basal or squamous cell skin cancer\n\n          -  History or evidence of inherited bleeding diathesis or coagulopathy,\n\n          -  History of thrombotic disorders within the last 6 months prior to enrollment (i.e.\n             cerebrovascular accident, transient ischemic attacks, subarachnoid hemorrhage),\n\n          -  Uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg)with or\n             without any anti-hypertensive medication ; patients with high initial blood pressure\n             are eligible if entry criteria are met after initiation or adjustment of\n             anti-hypertensive medication,\n\n          -  Any of the following within 6 months prior to enrollment:\n\n        myocardial infarction, severe/unstable angina, or coronary/peripheral artery bypass graft\n        surgery, clinically symptomatic and uncontrolled cardiovascular disease, or clinically\n        significant cardiac arrhythmias (grade 3-4)\n\n          -  Severe resting dyspnea due to complications or oxygen dependency,\n\n          -  Diabetic patient treated with oral anti-diabetics or insulin with an underlying\n             cardiopathy at ultrasound,\n\n          -  Any other severe acute illness such as active uncontrolled infections that would\n             preclude the safe administration of study therapy at the time of the enrolment\n\n          -  Other severe underlying medical conditions, which could impair the ability to\n             participate in the study\n\n          -  Major surgery, significant traumatic injury within 28 days prior to study treatment\n             start or anticipation of the need for major surgery during study treatment,\n\n          -  Minor surgery, including insertion of an indwelling catheter, within 24 hours prior\n             to the first bevacizumab infusion,\n\n          -  Non-healing wound, active peptic ulcer or bone fracture,\n\n          -  History of abdominal fistula, diagnosed with a trachea-oesophageal fistula or any\n             grade 4 non gastro-intestinal fistula, gastrointestinal perforation or\n             intra-abdominal abscess within 6 months of enrolment,"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 25, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880385", 
            "org_study_id": "ML25168"
        }, 
        "intervention": [
            {
                "arm_group_label": "bevacizumab, inflammatory breast cancer", 
                "description": "During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Biological", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "bevacizumab, inflammatory breast cancer", 
                "description": "Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "bevacizumab, inflammatory breast cancer", 
                "description": "Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles", 
                "intervention_name": "epirubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "bevacizumab, inflammatory breast cancer", 
                "description": "Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles", 
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "bevacizumab, inflammatory breast cancer", 
                "description": "Adjuvant: 100 mg/m2 q3w, 4 cycles", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "bevacizumab, inflammatory breast cancer", 
                "description": "Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fluorouracil", 
                "Docetaxel", 
                "Trastuzumab", 
                "Bevacizumab", 
                "Epirubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bevacizumab", 
            "inflammatory breast cancer", 
            "non metastatic", 
            "Avastin"
        ], 
        "lastchanged_date": "June 14, 2013", 
        "location": {
            "contact": {
                "email": "ghozlane_lakhoua@hotmail.fr", 
                "last_name": "ghozlane lakhoua", 
                "phone": "00 216 98 354 190"
            }, 
            "facility": {
                "address": {
                    "city": "Bab Saadoun", 
                    "country": "Tunisia", 
                    "state": "Tunis", 
                    "zip": "1006+"
                }, 
                "name": "Institut Salah Azaiz"
            }, 
            "investigator": {
                "last_name": "henda raies, professor", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Tunisia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy & Safety of Bevacizumab as Neoadjuvant Treatment in Patients With Locally Advanced Inflammatory Breast Cancer, a Pilot Study.", 
        "overall_contact": {
            "email": "ghozlane_lakhoua@hotmail.fr", 
            "last_name": "ghozlane lakhoua", 
            "phone": "0021698354190"
        }, 
        "overall_official": {
            "affiliation": "Institut Salah Azaiz", 
            "last_name": "amel mezlini, professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Tunisia : Direction de la pharmacie et du m\u00e9dicament", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of the pathologic complete response (pCR) rate among patients treated by 4 cycles of FEC100 and bevacizumab", 
            "measure": "pathologic Complete Response (pCR)", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "reference": {
            "PMID": "16391297", 
            "citation": "Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006 Feb 10;24(5):769-77. Epub 2006 Jan 3."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880385"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation of the safety of administering bevacizumab in the neoadjuvant setting, with particular attention on the incidence of grade 3/4 adverse events", 
                "measure": "Toxicity as assessed by CTCAE v3.0", 
                "safety_issue": "Yes", 
                "time_frame": "3 and 5 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "3 and 5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 and 5 years"
            }
        ], 
        "source": "Association Tunisienne de lutte Contre le Cancer", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Hoffmann-La Roche", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Sanofi", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Association Tunisienne de lutte Contre le Cancer", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}